The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in ...

Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with ...

The TouCAHn trial is an open-label, global, Phase 2 study designed to evaluate the efficacy, safety, and pharmacokinetics of atumelnant when ...

Please provide your email address to receive an email when new articles are posted on . Click here to read the Cover Story, “After decades with only one option, new therapies emerge for congenial ...

New CAHtalyst™ Pediatric and CAHtalyst™ Adult Phase 3 Clinical Study Data in Congenital Adrenal Hyperplasia CAHtalog™ Registry Data Highlighting Impact of Supraphysiologic Glucocorticoid Dosing Phase ...

Steroid biosynthesis is affected in the AR disorder known as congenital adrenal hyperplasia (CAH): the majority of cases are due to 21-hydroxylase deficiency. Androgen excess affects women’s ...

CAHtalyst™ Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline Daily Glucocorticoid Dose with Androgen Control Key Secondary Endpoint Achieved Statistically ...

- CAHtalyst™ Adult Phase 3 Study Met Primary and Important Key Secondary Endpoints, with Crinecerfont Treatment Decreasing Androstenedione Levels and Enabling Glucocorticoid Dose Reduction While ...

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced positive ...

Hormonal measurements and HLA genotyping of amniotic fluid at midgestation correctly predicted the postnatal dx of CAH in 26 of 29 fetuses at risk for CAH. Of these 26, 6 were predicted to have ...

The traditional view of nonclassic congenital adrenal hyperplasia is that affected individuals are not glucocorticoid-deficient. The results of a French study now cast doubts on this assumption, ...

New, Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, Proceedings of the National Academy of Sciences of the United States of America, Vol.